• Oculogica

  Led · Grant · May 2021

  Oculogica develops EyeBOX, an eye-tracking, FDA-cleared, baseline-free aid for diagnosing and categorizing concussion. The EyeBOX is a four-minute test intended for ages 5 to 67 and is already used by leading healthcare organizations. The company announced a $2 million U.S. Army Medical Research and Development Command (USAMRDC) grant to develop a wearable version of its technology for deployed and far-forward settings. That effort will involve partners including Keller Army Hospital at West Point, The Geneva Foundation, Children’s Hospital of Philadelphia, and the University of Wisconsin–Green Bay. AdHawk Microsystems’ camera-free eye-tracking technology will be a critical component of the new wearable device. Oculogica has previously received grants from the NIH and the FDA; the USAMRDC award is the largest grant the company has received to date. Oculogica is the company behind the EyeBOX device. The EyeBOX is being distributed at Level I, II and III trauma centers nationwide. The company recently closed an $8 million financing round. Sofia Fund, an existing backer, participated in the round. Proceeds will support further commercial distribution and deployment, including additional units for use with the U.S. Department of Defense.

• Neuravi

  Participated · Grant · Jul 2012

  Neuravi designs, develops and manufactures medical devices exclusively for the treatment of acute ischemic stroke. Its core product is the EmboTrap Revascularization Device, engineered with a proprietary dual-layer stent-like structure and an integrated distal protection zone to retrieve clot and reduce fragmentation. EmboTrap II has launched in Europe and the EmboTrap is available for investigational use in the U.S. under the ARISE II pivotal study, which will support an FDA submission. Through the Neuravi Thromboembolic Initiative, the company supports collaboration between engineers, clinicians and researchers and is building a pipeline of products focused on acute ischemic stroke. Neuravi announced €15 million in venture debt financing from IPF Partners to invest in U.S. commercialization and further R&D for its product pipeline. The company intends to commercialize this pipeline globally in the years ahead and aims to broaden the treatment toolbox available to stroke clinicians. Neuravi develops the EmboTrap Revascularization Device, a stent-like, dual-layer thrombectomy device with an integrated distal protection zone designed to capture and retain clot while reducing embolization risk. The EmboTrap is CE marked and commercially available in Europe and remains investigational in the United States. In a 42-patient case series presented at ESOC, treatment with EmboTrap restored significant blood flow in 86% of patients, with the majority recovering functional independence. The company supports collaborative research through the Neuravi Thromboembolic Initiative (NTI) to deepen understanding of clot mechanics and inform device design. Proceeds from the recent financing will fund European commercialization and the ARISE II clinical trial, which will begin enrolling patients this year at select U.S. and European centers. Neuravi is led by a team experienced in endovascular device development and global commercialization. Neuravi Limited is an Irish medical device company focused on developing a device to retrieve blood clots. The company’s core product aims to lower rates of ischemic stroke by removing occlusive clots. Neuravi completed a Series A financing to support further development of that device. The financing totaled $6.5 million (€5.2 million). The round was led by Fountain Healthcare Partners and Delta Partners. Proceeds are intended to advance the device’s development work.

No current team members are available.